Capital Counsel LLC Ionis Pharmaceuticals Inc Transaction History

Capital Counsel LLC

$2.18 Billion
Q1 2024

A detailed history of Capital Counsel LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Capital Counsel LLC holds 39,580 shares of IONS stock, worth $1.89 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

39,580

Previous 40,080 1.25%

Holding current value

$1.89 Million

Previous $2.03 Million 15.39%

% of portfolio

0.08%

Previous 0.1%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$42.03 - $53.55 $21,015 - $26,775	-500 Reduced 1.25%	39,580 $1.72 Million
Q4 2023 Feb 14, 2024	SELL	$43.39 - $51.63 $6,508 - $7,744	-150 Reduced 0.37%	40,080 $2.03 Million
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $28,501 - $37,954	-780 Reduced 1.9%	40,230 $1.78 Million
Q1 2022 May 16, 2022	BUY	$29.88 - $37.04 $12,848 - $15,927	430 Added 1.06%	41,010 $1.52 Million
Q2 2021 Aug 12, 2021	SELL	$34.54 - $47.25 $51,810 - $70,875	-1,500 Reduced 3.56%	40,580 $1.62 Million

Q3 2020 Nov 16, 2020	BUY	$47.45 - $62.95 $128,115 - $169,965	2,700 Added 6.86%	42,080 $2 Million
Q2 2019 Aug 14, 2019	SELL	$62.09 - $86.14 $310,450 - $430,700	-5,000 Reduced 11.27%	39,380 $2.53 Million
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $52,920 - $81,170	1,000 Added 2.31%	44,380 $3.6 Million
Q2 2018 Aug 14, 2018	BUY	$40.53 - $50.7 $40,530 - $50,700	1,000 Added 2.36%	43,380 $1.81 Million
Q1 2018 May 14, 2018	BUY	$44.08 - $55.05 $48,488 - $60,555	1,100 Added 2.66%	42,380 $1.87 Million
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $1.88 Million - $2.46 Million	41,280	41,280 $2.09 Million

Others Institutions Holding IONS

# of Institutions

396

Shares Held

122M

Call Options Held

854K

Put Options Held

464K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $6.76B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Counsel LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Counsel LLC with notifications on news.

Account

Capital Counsel LLC Ionis Pharmaceuticals Inc Transaction History